Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 10/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 4/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7028521 | 0.81 | EGLN2 (0.40) | KCNA5 | |
| SCHEMBL6743525 | 0.81 | CCR2 (0.44) | GRIN2BNAMPTPGRCCR2FAAH | |
| SCHEMBL6995882 | 0.80 | DRD3 (0.52) | NAMPT | |
| SCHEMBL6737659 | 0.80 | EPHX2 (0.48) | GRIN2BPDGFRBKCNA5NAMPTCCR2 | |
| SCHEMBL7035866 | 0.80 | HRH3 (0.49) | KCNA5 | |
| SCHEMBL6738742 | 0.79 | HRH2 (0.45) | KCNA5 | |
| SCHEMBL6733799 | 0.79 | FAAH (0.47) | GRIN2BPDGFRBNAMPTFAAH | |
| SCHEMBL6740762 | 0.78 | CCR2 (0.56) | GRIN2BNAMPTCCR2FAAH | |
| SCHEMBL6738695 | 0.77 | NAMPT (0.46) | GRIN2BNAMPTPGRCCR2FAAH | |
| SCHEMBL6742058 | 0.77 | NAMPT (0.56) | GRIN2BNAMPTPGRCCR2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | US | disclosed |
| WO-2000077000-A9 | NEW BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2003-06-19 | — | — | WO | disclosed |
| EP-1192157-A1 | BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000077000-A1 | NEW BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ADRA1B, ADRB2, ADRA1D | GRIN2B 549/4885PDGFRB 3911/4885KCNA5 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.